Hengrui Medicine (01276): SHR-8925 for Injection Approved to Conduct Clinical Trials

Zhitong Finance APP news, Hengrui Pharmaceuticals (01276) announced that recently, the company's subsidiary Suzhou Shengdiya Biomedical Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (hereinafter referred to as the "NMPA") for the investigational drug SHR-8925 for injection, and will commence clinical trials in the near future.